Anne Rowling Clinic researcher wins drug safety prize

30 June 2015

Dr David Hunt, a Clinical Fellow who works at the Anne Rowling Clinic, has been awarded the Sir Derrick Dunlop Prize for contribution to drug safety.

The Dunlop Prize was awarded by by the Medicines and Healthcare Products Regulatory Agency (MHRA) at a special conference to mark the 50th anniversary of the Yellow Card Scheme at the Royal College of Physicians in Edinburgh.

The prize is named in honour of Sir Derrick Dunlop, who established the Yellow Card Scheme in 1964 and recognises clinicians who have made an important contribution to drug safety through reporting.

The award was in recognition of Dr Hunt’s role in identifying the link between recombinant interferon-beta therapy and a potentially fatal disease of small blood vessels called thrombotic microangiopathy. The identification of this serious adverse drug reaction led to the world-wide implementation of measures to reduce risk to patients.

Dr Hunt is a Wellcome Trust Intermediate Clinical Fellow and works with Professor Andrew Jackson at the MRC Institute of Genetics and Molecular Medicine at the University of Edinburgh, studying how innate immune activation and interferon can cause inflammatory disease.

It is a great honour to receive this prize from the MHRA, which reflects the work of a number of colleagues across the UK who contributed to the identification of this important drug safety problem.

Dr David Hunt, Clinical Fellow, Anne Rowling Clinic


Dr Hunt’s findings were published earlier in the year. Read the article in the New England Journal of Medicine.

See David Hunt's profile on our Staff page.

Back to news